Media coverage about Psychemedics (NASDAQ:PMD) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Psychemedics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.0351427189856 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Psychemedics (NASDAQ PMD) opened at $21.27 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.72 and a quick ratio of 2.72. The company has a market capitalization of $116.82, a PE ratio of 19.16 and a beta of 0.95. Psychemedics has a 1 year low of $13.81 and a 1 year high of $27.99.
Psychemedics (NASDAQ:PMD) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $0.25 earnings per share for the quarter. The company had revenue of $10.05 million during the quarter. Psychemedics had a return on equity of 37.33% and a net margin of 15.06%.
Separately, BidaskClub upgraded Psychemedics from a “sell” rating to a “hold” rating in a research report on Saturday, November 4th.
TRADEMARK VIOLATION NOTICE: This report was originally published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.thestockobserver.com/2018/01/14/psychemedics-pmd-earning-somewhat-positive-news-coverage-report-finds.html.
Psychemedics Company Profile
Psychemedics Corporation (Psychemedics) provides hair testing for drugs of abuse, utilizing a hair analysis method involving digestion of hair, enzyme immunoassay (EIA) technology and confirmation by mass spectrometry to analyze human hair to detect abused substances. The Company operates in drug testing services segment.
Receive News & Ratings for Psychemedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics and related companies with MarketBeat.com's FREE daily email newsletter.